A platform employing small molecule X-bonded polyphenols to potentially improve potency, efficacy, bioavailability, and permeability of biopharmaceuticals, while ensuring safety and tolerability
Polyphenols exhibit properties that are beneficial in combating various diseases and conditions, including cancer, neuronal diseases, cardiac diseases, metabolic disorders, and immunity-related issues. Additionally, they possess antimicrobial, anti-inflammatory, and antioxidant properties.
*Source: ResearchGate
Linebacker-1 and -2 are potential monotherapies and/or co-therapies in colon and lung cancer, and other oncology applications. Patent issued in the United States.
Approved
Linebacker-1 and -2 are compounds with potential application in inflammatory disorders. Patent issued in the United States.
Approved
Linebacker-1 and -2 are compounds with potential application in neurological disorders. Patent issued in the United States.
Approved
Lung and colon cancer are the two leading causes of cancer deaths worldwide (World Health Organization). Linebacker down-regulates PIM (proviral integration site for Moloney murine leukemia virus) kinase which plays a key role as an oncogene in solid tumor cancers. With continued development through the pre-clinical and registration phases, Linebacker-1 and Linebacker-2 compounds are new potential treatment options in oncology.
Prophase Labs (NASDAQ: PRPH) is a global development & commercialization partner with a focus on oncology (lung & colon cancer), neurology and inflammatory disease.
Pre-clinical studies are ongoing.
Get the latest news delivered to your inbox
